[{"NetIncomeLoss_1_Q3_USD":-21659000.0,"EquityMethodInvestments_0_Q3_USD":4017000.0,"DeferredRentCreditCurrent_0_Q3_USD":384000.0,"GeneralAndAdministrativeExpense_3_Q3_USD":20946000.0,"GeneralAndAdministrativeExpense_1_Q3_USD":7669000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":41961691.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":42148837.0,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_3_Q3_USD":-1.35,"IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_1_Q3_USD":-0.51,"CommitmentsAndContingencies_0_Q3_USD":null,"AccruedLiabilitiesCurrent_0_Q3_USD":11304000.0,"OperatingLeasesRentExpenseNet_3_Q3_USD":1100000.0,"OperatingLeasesRentExpenseNet_1_Q3_USD":400000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":25000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-196051000.0,"Depreciation_3_Q3_USD":239000.0,"AssetsCurrent_0_Q3_USD":278902000.0,"PrepaidExpenseAndOtherAssets_0_Q3_USD":2083000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":5393348.0,"StockIssuedDuringPeriodValueStockOptionsExercised_3_Q3_USD":512000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":69000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":25000.0,"IncreaseDecreaseInOtherNoncurrentLiabilities_3_Q3_USD":96000.0,"Liabilities_0_Q3_USD":13345000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_3_Q3_USD":-56821000.0,"AccruedProfessionalFeesCurrent_0_Q3_USD":1056000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":13923000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":36597000.0,"IncreaseDecreaseInAccruedLiabilities_3_Q3_USD":2319000.0,"OperatingLeasesFutureMinimumPaymentsDueInThreeYears_0_Q3_USD":135000.0,"CommonStockValue_0_Q3_USD":4000.0,"InvestmentIncomeNet_1_Q3_USD":63000.0,"InvestmentIncomeNet_3_Q3_USD":1156000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":428000.0,"IncreaseDecreaseInOtherCurrentAssets_3_Q3_USD":281000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q3_USD":276800000.0,"OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_0_Q3_USD":338000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q3_USD":-21659000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_3_Q3_USD":-56846000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-21590000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-56821000.0,"IncreaseDecreaseInAccountsPayable_3_Q3_USD":-1590000.0,"OtherAssetsNoncurrent_0_Q3_USD":1440000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":84831000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":512000.0,"CommonStockSharesIssued_0_Q3_shares":43128804.0,"IncreaseDecreaseInDeferredLiabilities_3_Q3_USD":-271000.0,"Assets_0_Q3_USD":286100000.0,"CommonStockSharesOutstanding_0_Q3_shares":43128804.0,"RestrictedCashNoncurrent_0_Q3_USD":565000.0,"PaymentsToAcquireMarketableSecurities_3_Q3_USD":191963000.0,"PaymentsToAcquireEquityMethodInvestments_3_Q3_USD":3500000.0,"IncomeLossFromEquityMethodInvestments_3_Q3_USD":-459000.0,"IncomeLossFromEquityMethodInvestments_1_Q3_USD":-130000.0,"OperatingLeasesFutureMinimumPaymentsDueInTwoYears_0_Q3_USD":1297000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-47257000.0,"LiabilitiesCurrent_0_Q3_USD":12752000.0,"AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_1_Q3_USD":3043000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_3_Q3_USD":-242796000.0,"NonoperatingIncomeExpense_3_Q3_USD":1156000.0,"NonoperatingIncomeExpense_1_Q3_USD":63000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q3_USD":85396000.0,"ProceedsFromStockOptionsExercised_3_Q3_USD":512000.0,"OtherAccruedLiabilitiesCurrent_0_Q3_USD":315000.0,"AdditionalPaidInCapital_0_Q3_USD":402601000.0,"NumberOfOperatingSegments_3_Q3_segment":1.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":1176000.0,"NetIncomeLoss_3_Q3_USD":-56846000.0,"AccountsPayableCurrent_0_Q3_USD":1064000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q3_USD":-21590000.0,"AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation_3_Q3_USD":6992000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-129875000.0,"OtherComprehensiveIncomeLossNetOfTax_3_Q3_USD":25000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":69000.0,"ShareBasedCompensation_3_Q3_USD":6992000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":0.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.0001,"LitigationSettlementExpense_3_Q3_USD":0.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":-1626000.0,"CommonStockSharesAuthorized_0_Q3_shares":150000000.0,"OperatingIncomeLoss_3_Q3_USD":-57543000.0,"MarketableSecurities_0_Q3_USD":191988000.0,"OperatingIncomeLoss_1_Q3_USD":-21592000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q3_USD":3174000.0,"OperatingExpenses_3_Q3_USD":57543000.0,"OperatingExpenses_1_Q3_USD":21592000.0,"ProfitLoss_3_Q3_USD":-56846000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":96000.0,"OperatingLeasesFutureMinimumPaymentsDueCurrent_0_Q3_USD":1372000.0,"StockholdersEquity_0_Q3_USD":272755000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":588000.0,"DeferredRentCreditNoncurrent_0_Q3_USD":497000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":286100000.0,"OperatingLeasesFutureMinimumPaymentsDue_0_Q3_USD":3142000.0,"Ticker":"SWTX","CIK":"1773427","name":"SPRINGWORKS THERAPEUTICS, INC.","OfficialName":"SpringWorks Therapeutics Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"2504354261.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201112"}]